Cytotoxicity Testing for Medical Devices: Standards, Methods, and Evaluation Per ISO 10993-5

In vitro cytotoxicity testing is the cornerstone of biological safety evaluation for medical devices, detecting whether device materials or their leachable substances cause cell death, growth inhibition, or other adverse effects in mammalian cell cultures. Performed in accordance with ISO 10993-5 and ISO 10993-12 (or their Chinese equivalents, GB/T 16886.5 and GB/T 16886.12), cytotoxicity testing is a mandatory baseline requirement for medical device registration in virtually every major market. This technical article explains the principles, sample requirements, test methods, acceptance criteria, and practical applications of cytotoxicity testing for medical devices.

Technical Overview

Cytotoxicity testing evaluates whether a medical device, its constituent materials, or substances that migrate out of them can damage living cells. It is widely regarded as the most sensitive and broadly applicable of the in vitro biocompatibility tests in the ISO 10993 series, serving as an early screening indicator of potential local tissue effects such as inflammation, necrosis, and impaired wound healing. Under the risk-based biological evaluation framework of ISO 10993-1, in vitro cytotoxicity is a mandatory baseline test for all device categories, regardless of the nature of body contact (surface, external communicating, or implant) or the duration of contact (limited, prolonged, or permanent).

The core test method is defined in ISO 10993-5, "Biological evaluation of medical devices — Part 5: Tests for in vitro cytotoxicity," while ISO 10993-12 governs sample selection, preparation, and extraction conditions. In China, the corresponding national standards are GB/T 16886.5 and GB/T 16886.12, which are technically aligned with the ISO documents. The standard recognizes three test categories — extract (elution), direct contact, and indirect contact — and two evaluation modes: qualitative microscopic grading of cell morphology and lysis on a 0 to 4 reactivity scale, and quantitative measurement of cell viability using colorimetric endpoints such as MTT reduction or neutral red uptake. A test article is considered non-cytotoxic when measured cell viability remains at or above 70% of the negative (blank) control value.

Testing is typically performed at accredited third-party laboratories or in-house biosafety facilities using established, validated cell lines, with L929 mouse fibroblasts being the most widely used. Each test run includes a negative control material (such as high-density polyethylene) and a positive control chemical (such as zinc sulfate solution or sodium dodecyl sulfate) to confirm the responsiveness and validity of the test system.

Testing Samples

The test article should represent, as closely as possible, the product in its final clinical condition. Whenever feasible, the finished device after final manufacturing, assembly, cleaning, and sterilization is preferred over raw materials, because processing aids, sterilant residues, and degradation products may contribute to cytotoxicity.

Final Device Products

Complete finished devices or representative sections of the device, tested in their sterilized, ready-to-use state. This is the preferred sample type for regulatory submission, as it captures the cumulative effect of all materials, additives, surface treatments, and sterilization by-products.

Raw Materials and Polymer Specimens

Sheets, films, granules, cured plaques, or molded coupons of constituent materials such as silicone elastomers, polyurethanes, PVC compounds, polyethylene, biodegradable polymers, or metal alloys. These are commonly tested during early development and material screening, provided the specimens are processed, cured, and cleaned identically to the production route.

Coatings, Adhesives, Printing Inks, and Small Components

Surface coatings (hydrophilic, antimicrobial, drug-eluting), bonding adhesives, label inks, and other functional components are tested individually when they contribute to patient-contacting surfaces, often using the extract method with appropriate surface-area-based extraction ratios.

Primary Packaging and Combination Products

Packaging materials that directly contact the device, container-closure systems for drug-device and biologic-device combination products, and drug-contacting delivery components may also require cytotoxicity evaluation, particularly when extractables and leachables can transfer to the patient.

Testing Items

A complete cytotoxicity evaluation typically encompasses the following test items and deliverables, depending on the method selected and the regulatory objective:

• Qualitative cytotoxicity assessment: microscopic evaluation of cell morphology, vacuolization, detachment, and lysis, graded on the 0–4 reactivity scale defined in ISO 10993-5
• Quantitative cell viability determination using validated colorimetric endpoints, including MTT, XTT, WST-1/WST-8 (CCK-8), neutral red uptake (NRU), kenacid blue total protein, or colony forming efficiency (CFE)
• Cytotoxicity testing of extracts prepared with serum-supplemented culture medium and, where applicable, additional extraction vehicles (polar and non-polar)
• Sample preparation and extraction documentation per ISO 10993-12: extraction ratio, extraction conditions, extraction vehicle, and particle-fluid interaction controls
• Control validation: negative control material (high-density polyethylene or equivalent) and positive control chemical (for example, 0.1% zinc sulfate heptahydrate solution or sodium dodecyl sulfate) with defined acceptance limits
• Dose-response or dilution-series testing (for example, 100%, 50%, and 25% extract concentrations) to support interpretation of borderline results and risk assessment
• Comprehensive test report with methodology, raw and calculated data, photographic or micrographic evidence, control results, and a conclusion on the cytotoxic potential of the test article

Testing Methods

ISO 10993-5 describes three principal test formats. The choice among them depends on the device geometry, the nature of patient contact, the physical form of the sample, and the leachability of its constituents.

Sample Preparation and Extraction (ISO 10993-12)

For the extract method, the test article is incubated in an extraction vehicle, typically serum-supplemented minimum essential medium (MEM), under conditions designed to simulate or exaggerate clinical exposure. Standard surface-area or mass-to-volume ratios are prescribed:

• Thin films and sheets with a thickness below 0.5 mm: 6 cm² of surface area per mL of vehicle
• Sheets and plates with a thickness of 0.5 mm to 1 mm: 3 cm² per mL
• Elastomeric materials thicker than 1 mm: 1.25 cm² per mL
• Irregularly shaped solids: 0.1 g to 0.2 g of material per mL, or 6 cm² per mL when the surface area can be determined

Extraction is commonly performed at 37 °C ± 1 °C for 24 h ± 2 h, which is the preferred condition for cytotoxicity because it matches cell culture temperature. Exaggerated conditions, such as 50 °C for 72 h, 70 °C for 24 h, or 121 °C for 1 h, may be used for screening purposes or for chemically unstable materials, provided the extraction does not alter the material itself.

Extract (Elution) Test

The extract test is the most widely applied method and is suitable for the majority of medical devices. The test article is extracted as described above, and the resulting extract is applied to a near-confluent monolayer of L929 fibroblasts (or another validated cell line) for 24 to 48 hours. Both qualitative morphological grading and quantitative viability measurements can be performed on the same test system. Because the method captures all leachable substances, it is particularly relevant for evaluating the aggregate cytotoxic potential of complex devices.

Direct Contact Test

In the direct contact test, a portion of the test article is placed directly onto the cell monolayer and incubated for approximately 24 hours. This method is appropriate for low-density materials, absorbents, and devices where leaching is limited but surface contact is clinically relevant. Care is taken to minimize physical (mechanical) damage to the cells, and the sample-to-cell contact area is documented. Cytotoxicity is graded by examining the zone of malformed, degenerated, or lysed cells beneath and around the specimen.

Indirect Contact Tests (Agar Diffusion and Filter Diffusion)

The agar diffusion (agar overlay) test is designed for higher-density materials that could mechanically damage a monolayer. Cells are covered with a thin layer of nutrient agar, the test article is placed on the agar surface, and leached substances diffuse through the agar to reach the cells. After incubation and neutral red staining, the zone of decolorization or lysis is measured. The filter diffusion test uses cells grown on a cellulose acetate membrane filter; the test article is applied briefly to the filter, after which cells are fixed and stained to reveal cytotoxic zones. This format is well suited to detecting low-molecular-weight leachables.

Quantitative Viability Assays and Acceptance Criteria

Quantitative endpoints convert cellular metabolic activity into an optical density signal. In the MTT assay, viable cells reduce yellow 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide to purple formazan crystals, which are solubilized and measured spectrophotometrically at approximately 570 nm. Neutral red uptake measures lysosomal accumulation of the dye in viable cells, while WST/XTT and ATP-based assays provide alternative metabolic readouts. Cell viability is calculated as a percentage of the untreated blank control. Per ISO 10993-5, viability of 70% or greater relative to the blank indicates the test article has no significant cytotoxic potential; values below 70% indicate a cytotoxic potential requiring further investigation. For qualitative grading, reactivity grades of 0 (none), 1 (slight), and 2 (mild) are generally considered acceptable, whereas grades 3 (moderate) and 4 (severe) indicate cytotoxicity.

Controls and Test Validity

Every run must include a negative control material (commonly high-density polyethylene) to confirm the absence of background cytotoxicity, and a positive control such as a dilute zinc sulfate or sodium dodecyl sulfate solution to demonstrate that the test system can detect a known cytotoxic challenge. A vehicle or blank control is included for quantitative assays. Acceptance limits for control performance are predefined in the test protocol; runs failing these limits are repeated.

Applications

Cytotoxicity test data support medical device safety evaluation across the entire product lifecycle, from research and development to post-market surveillance. Typical applications include:

• Regulatory submissions for device registration, including NMPA filings in China, FDA 510(k) and PMA submissions in the United States, CE technical documentation under the EU MDR, and submissions to other national authorities
• Baseline biocompatibility documentation within the biological evaluation plan and report required by ISO 10993-1
• Material selection, formulation comparison, and supplier qualification during design and development
• Change control assessment when materials, suppliers, manufacturing processes, or sterilization methods are modified
• Evaluation of sterilization effects, including ethylene oxide residuals and radiation-induced degradation products
• Support for extractables and leachables studies, chemical characterization (ISO 10993-18), and toxicological risk assessment (ISO 10993-17)
• Shelf-life and stability programs, and root-cause investigation of adverse biological events

Cytotoxicity results are normally interpreted together with other endpoints of the ISO 10993 series, such as sensitization (ISO 10993-10), intracutaneous irritation (ISO 10993-23), hemocompatibility (ISO 10993-4), and genotoxicity (ISO 10993-3), with the exact test battery determined by the contact classification and duration specified in ISO 10993-1.

FAQ

Which standards govern medical device cytotoxicity testing?

The test method is specified in ISO 10993-5 (GB/T 16886.5 in China), while sample selection, sectioning, extraction ratios, and extraction conditions follow ISO 10993-12 (GB/T 16886.12). The overall test strategy is established under ISO 10993-1. Related pharmacopeial methods, such as USP In Vitro Biological Reactivity Tests, are also referenced for certain product categories.

What is the pass criterion for cytotoxicity?

For quantitative assays, cell viability of at least 70% of the blank control indicates the sample is not considered cytotoxic. For qualitative assessment, reactivity grades of 0 to 2 are generally acceptable; grades 3 and 4 indicate cytotoxic potential. Borderline results are typically confirmed through repeat testing, extract dilution studies, or chemical characterization.

Which cell line is used?

ISO 10993-5 permits any validated, authenticated mammalian cell line. The L929 mouse fibroblast line is the most commonly used worldwide; BALB/3T3, V79, and other established lines are also accepted when scientifically justified.

How much sample is required?

Sample quantity depends on the extraction ratio: for example, at 6 cm²/mL with 10 mL of vehicle, at least 60 cm² of sample surface is needed. Irregular solids are dosed at 0.1 to 0.2 g/mL. Sufficient extra material should be supplied to accommodate duplicate extractions, repeat testing, and retained samples.

How long does the test take?

A standard extract test with MTT typically requires approximately two to three weeks from cell thawing and subculture through extraction, dosing, viability measurement, and report issuance. Direct and indirect contact assays follow a similar timeline, provided cells are available in log-phase growth at dosing.

How do I choose between the extract, direct contact, and indirect contact methods?

The extract test is the default choice for most devices because it detects the full spectrum of leachables. Direct contact is suitable for low-density materials and clinically relevant surface-contact scenarios; agar or filter diffusion is used when direct placement would mechanically damage the monolayer or when rapid diffusion of small molecules is of interest. Method selection should be justified by the contact analysis in ISO 10993-1.

What happens if a sample fails the cytotoxicity test?

A failure triggers investigation rather than immediate rejection. Common follow-up actions include retesting with serial extract dilutions to estimate cytotoxic potency, reviewing extraction conditions, performing chemical characterization and toxicological risk assessment to identify the causative leachable, and evaluating material or process changes such as alternative additives, post-curing, or a different sterilization modality.

Is cytotoxicity testing alone sufficient for regulatory submission?

For most devices, cytotoxicity is only one component of the baseline battery. Regulators typically also expect sensitization and irritation data at minimum, with additional endpoints (hemocompatibility, genotoxicity, subacute toxicity, implantation) selected according to the device contact category and duration as defined in ISO 10993-1.